Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics Limited has issued 10,522 fully paid ordinary shares following the exercise of unlisted options, with a $0.65 exercise price. This move is part of the company’s compliance with the Corporations Act, allowing these shares to be sold without disclosure under certain exemptions, potentially enhancing liquidity and investor engagement.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited operates within the biotechnology industry, focusing on the development of novel therapeutics. The company is primarily engaged in creating treatments aimed at protecting brain cells and improving recovery following neurological conditions such as stroke.
Average Trading Volume: 94,515
Technical Sentiment Signal: Buy
See more data about AGN stock on TipRanks’ Stock Analysis page.